Exelixis EXEL
Exelixis Q3 FY24: revenue $539.5M; diluted EPS $0.40
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000939767-24-000150
Key figures from this report
These are the numbers Exelixis reported for Q3 FY24, the quarter ended Sep 27, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$539.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$118.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.40No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$258.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations$271.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
- BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
- Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
- United Therapeutics UTHR public float $11.2B, Jun 30, 2025
- Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
